ProBioGen, a Contract Development & Manufacturing Organization (CDMO), has partnered with DIOSynVax Ltd to manufacture DIOS-HFVac3, a trivalent hemorrhagic fever (HF) vaccine that was developed in collaboration with the Molecular Virology, Institute of Medical Microbiology and Hygiene, University of Regensburg.
 
The novel vaccine targets HF diseases caused by Ebola, Marburg, and Lassa viruses. The pre-clinical efficacy of the novel trivalent vaccine has been demonstrated in challenge studies in animal models. ProBioGen’s MVA CR19 vector will be used to deliver the three HF vaccine antigens.
 
DIOS-HFVac3 will be manufactured on ProBioGen’s industrial platform, which was developed to produce a broad range of viral vaccines. The platform consists of the company’s proprietary AGE1.CR.pIX suspension cell line, proprietary chemically defined media and advanced scalable production and purification process. Under the terms of the agreement, ProBioGen will conduct process and analytical development followed by manufacturing of DIOS-HFVac3 for clinical trials and subsequent regulatory approval.
 
“Our collaboration with DIOSynVax represents a significant milestone in ProBioGen’s journey,” said Dr. Volker Sandig, Chief Scientific Officer at ProBioGen. “Our innovative platform for the manufacturing of DIOS-HFVac3 underscores our commitment to advancing robust and resilient biopharmaceutical solutions for global health challenges, independent of the geographic region where these challenges may occur.”
 
“We are delighted to continue our fruitful partnership with ProBioGen,” stated DIOSynVax’s CEO, Prof. Jonathan Heeney. “Their expertise, dedication, and collaborative spirit have been instrumental in our joint efforts. Together, we are poised to make a significant impact by bringing this vital vaccine to developing countries, mainly in Africa.”
 
This research is funded by the Department of Health and Social Care as part of the UK Vaccine Network (UKVN), a UK Aid program to develop vaccines for diseases with epidemic potential in low and middle-income countries (LMICs).

More ProBioGen News